tradingkey.logo

Exagen Inc

XGN
9.360USD
-1.020-9.83%
Market hours ETQuotes delayed by 15 min
210.70MMarket Cap
LossP/E TTM

Exagen Inc

9.360
-1.020-9.83%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Exagen Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Exagen Inc's Score

Industry at a Glance

Industry Ranking
22 / 78
Overall Ranking
136 / 4615
Industry
Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 8 analysts
Buy
Current Rating
14.857
Target Price
+43.83%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Exagen Inc Highlights

StrengthsRisks
Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 22.12% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 55.64M.
Undervalued
The company’s latest PE is -11.09, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 13.24M shares, increasing 15.13% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 681.62K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.96.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 8.59, which is higher than the Healthcare Providers & Services industry's average of 7.24. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 17.24M, representing a year-over-year increase of 37.87%, while its net profit experienced a year-over-year increase of 40.95%.

Score

Industry at a Glance

Previous score
8.59
Change
0

Financials

7.63

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

7.68

Operational Efficiency

10.00

Growth Potential

10.00

Shareholder Returns

7.63

Exagen Inc's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 7.51, which is higher than the Healthcare Providers & Services industry's average of 7.09. Its current P/E ratio is -11.09, which is -92.99% below the recent high of -0.78 and -20.72% above the recent low of -13.39.

Score

Industry at a Glance

Previous score
7.51
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 22/78
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 8.50, which is higher than the Healthcare Providers & Services industry's average of 7.56. The average price target for Exagen Inc is 15.00, with a high of 18.00 and a low of 11.00.

Score

Industry at a Glance

Previous score
8.50
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts
Buy
Current Rating
14.857
Target Price
+43.83%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

64
Total
7
Median
9
Average
Company name
Ratings
Analysts
Exagen Inc
XGN
8
CVS Health Corp
CVS
30
HCA Healthcare Inc
HCA
27
Teladoc Health Inc
TDOC
26
Tenet Healthcare Corp
THC
24
Universal Health Services Inc
UHS
22
1
2
3
...
13

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 7.21, which is higher than the Healthcare Providers & Services industry's average of 6.96. Sideways: Currently, the stock price is trading between the resistance level at 11.88 and the support level at 9.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
7.18
Change
0.03

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.460
Neutral
RSI(14)
35.186
Neutral
STOCH(KDJ)(9,3,3)
28.650
Neutral
ATR(14)
0.444
High Vlolatility
CCI(14)
-169.782
Sell
Williams %R
69.811
Sell
TRIX(12,20)
0.240
Sell
StochRSI(14)
3.829
Oversold
Moving Average
Sell(5)
Neutral(0)
Buy(1)
Indicators
Value
Direction
MA5
10.996
Sell
MA10
11.435
Sell
MA20
11.510
Sell
MA50
10.698
Sell
MA100
9.378
Sell
MA200
7.165
Buy

Institutional Confidence

Currency: USD Updated: 2025-11-06

The company’s current institutional recognition score is 5.00, which is lower than the Healthcare Providers & Services industry's average of 6.96. The latest institutional shareholding proportion is 60.16%, representing a quarter-over-quarter decrease of 6.18%. The largest institutional shareholder is The Vanguard, holding a total of 681.62K shares, representing 3.10% of shares outstanding, with 11.31% increase in holdings.

Score

Industry at a Glance

Previous score
5.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Tullis Health Investors
1.81M
--
NMSIC Co-Investment Fund, L.P
1.76M
-16.60%
RTW Investments L.P.
1.70M
+12.24%
H.I.G. Capital, LLC
1.70M
--
TD Securities, Inc.
851.29K
-4.50%
Hunt Holdings, L.P
829.28K
-18.00%
Balyasny Asset Management LP
718.78K
--
The Vanguard Group, Inc.
Star Investors
681.62K
+38.84%
Silvercrest Asset Management Group LLC
531.77K
--
1
2

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 5.26, which is lower than the Healthcare Providers & Services industry's average of 5.45. The company's beta value is 1.79. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
5.26
Change
0
Beta vs S&P 500 index
1.79
VaR
+6.67%
240-Day Maximum Drawdown
+52.50%
240-Day Volatility
+107.51%

Return

Best Daily Return
60 days
+8.67%
120 days
+14.34%
5 years
+42.38%
Worst Daily Return
60 days
-8.96%
120 days
-8.96%
5 years
-24.63%
Sharpe Ratio
60 days
+1.04
120 days
+2.82
5 years
+0.28

Risk Assessment

Maximum Drawdown
240 days
+52.50%
3 years
+60.92%
5 years
+93.82%
Return-to-Drawdown Ratio
240 days
+2.80
3 years
+1.77
5 years
-0.08
Skewness
240 days
+1.18
3 years
+1.32
5 years
+1.47

Volatility

Realised Volatility
240 days
+107.51%
5 years
+102.00%
Standardised True Range
240 days
+4.65%
5 years
+4.57%
Downside Risk-Adjusted Return
120 days
+486.76%
240 days
+486.76%
Maximum Daily Upside Volatility
60 days
+33.12%
Maximum Daily Downside Volatility
60 days
+37.65%

Liquidity

Average Turnover Rate
60 days
+1.65%
120 days
+1.42%
5 years
--
Turnover Deviation
20 days
+95.54%
60 days
+153.91%
120 days
+118.45%

Peer Comparison

Healthcare Providers & Services
Exagen Inc
Exagen Inc
XGN
7.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Natera Inc
Natera Inc
NTRA
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Pediatrix Medical Group Inc
Pediatrix Medical Group Inc
MD
8.31 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ensign Group Inc
Ensign Group Inc
ENSG
8.31 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Encompass Health Corp
Encompass Health Corp
EHC
8.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lifestance Health Group Inc
Lifestance Health Group Inc
LFST
8.15 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI